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Abstract Despite recent advances in the understanding of Sjögren's Syndrome (SjS), the
pathogenic mechanisms remain elusive and an ideal model for early drug discovery is not yet
available. To establish a humanized mouse model of SjS, peripheral blood mononuclear cells
(PBMCs) from healthy volunteers or patients with SjS were transferred into immunodeficient
NOD-scid IL-2rγ(null) mouse recipients to produce chimeric mice. While no difference was
observed in the distribution of cells, chimeric mice transferred with PBMCs from SjS patients
produced enhanced cytokine levels, most significantly IFN-γ and IL-10. Histological examination
revealed enhanced inflammatory responses in the lacrimal and salivary glands of SjS chimeras,
as measured by digital image analysis and blinded histopathological scoring. Infiltrates were
primarily CD4+, with minimal detection of CD8+ T-cells and B-cells. These results demonstrate a
novel chimeric mouse model of human SjS that provides a unique in vivo environment to test
experimental therapeutics and investigate T-cell disease pathology.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Davis Medical Research Center,
c.edu (W.N. Jarjour).
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Sjögren's syndrome (SjS) is one of the most prevalent
autoimmune diseases, with affects ranging between 0.5 and
3% of a given population. Although systemic inflammatory480
isresponses are observed, this autoimmune diseasemainly affects
the salivary and lacrimal glands. Glandular histopathology is
primarily characterized by a CD4+ T-cell infiltrate [1]. Despite
the detection of B-cells in advanced lesions [2], T-cells
predominate the infiltrate and appear to mediate the cytotoxicMedical Center Dr, Columbus, OH 43210, USA. Fax: +1 614 293 5361.
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SjS (reviewed in [3]). While the trigger of the cellular
infiltration remains unknown, the pathogenesis of SjS is
currently thought to involve genetic, neuro-hormonal and
environmental factors, and to require participation of
the innate and the adaptive immune systems. Thus,
research concerning SjS development, progression, and
molecular-based therapeutics requires in vivo animal models.
Mouse models for SjS have been valuable in understanding
the contribution of these various factors, but the conclusions
reached from studies in these systems often do not translate
efficaciously into humans. Since ethical and technical con-
straints limit such studies in human systems, humanized mice,
or human-mouse chimeras, have been created to enable the
in vivo study of human cells and disease processes that would
not otherwise be possible. The transgenic mouse strain
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ is more commonly known
as NOD scid gamma (NSG) and cannot produce T-cells, B-cells,
or functional NK cells due to several targeted mutations. This
mouse has been shown to achieve successful human engraft-
ment using 10-fold fewer human peripheral bloodmononuclear
cells (PBMCs) than the preceding humanized mouse strains [4].
Moreover, NSG chimeras display no symptoms of graft versus
host disease with transfers of up to 20 × 106 human PBMCs for
at least 30 days, allowing a 4–5 week window for investigation
[5]. In addition, the NOD mouse has been shown to spontane-
ously develop sialoadenitis with infiltrates consisting primarily
of CD4+ T-cells and adoptive transfer of these cells into
NOD-scid mice recapitulated this autoimmune phenotype [6],
which suggests that there may already be an environment
conducive to SjS-like disease in NSG mice.
Aside from type 1 diabetes, NSG mice have not been used
extensively in the investigation of autoimmune disorders.
Here, we take advantage of the NSG model to engraft and
study SjS. The resulting SjS chimeras displayed enhanced
cytokine expression and target organ inflammation relative to
transfers from healthy controls. Further, histopathological
analysis revealed marked inflammation and tissue damage in
the salivary and lacrimal glands consisting primarily of CD4+
T-cell infiltrates. Collectively, this approach has provided a
novel platform to explore human-focused, molecular-based
therapies for targeting T-cells in SjS and more readily enables
the future translational application of these findings.
2. Materials and methods
2.1. Human samples and PBMC isolation
Patients meeting the revised American–European consensus
criteria for SjS (n = 4) [7] as well as age and sex-matched
healthy volunteers (n = 4) were recruited for the study from
The Ohio State University Wexner Medical Center (OSUWMC)
clinics, the Research Match program at OSUWMC, and the
American Red Cross. Participation was through an approved
Institutional Review Board protocol. PBMCswere isolated under
Ficoll gradient centrifugation as previously described [8].
2.2. Mice
4-week old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice
were obtained from The Jackson Laboratories. All animalmaintenance and protocols are approved by the Institutional
Animal Care and Use Committee at OSUWMC. Animal facility
was maintained at 22–23 °C and between 30 and 50% relative
humidity with a 12-hour light/dark cycle. Chow and water
were available ad libitum.
2.3. Adoptive transfers
Freshly isolated human PBMCs were injected intraperitoneally
into 8-week old NSG mice (5.0 × 106 cells/mouse); at least 3
mice were injected from each individual human sample.
Human PBMC preparations were washed in PBS and counted
using a hemocytometer with trypan blue to ensure cell
viability. All samples were kept separate and not pooled
before injections. Mice (n = 14 total for each experimental
condition; healthy or SjS) were monitored every other day,
including weights and physical signs of disease progression,
and sacrificed 4 weeks after adoptive transfer for blood and
tissue collection as described below.
2.4. Tissue collection and staining
Mouse tissues were dissected, submerged in neutral buffered
10% formalin, and transferred to 70% ethanol for paraffin
processing. Paraffin blocks were cut at 4 microns, placed on
positively charged slides, and fixed in cold acetone. Serial
paraffin sections were used for immunohistochemistry and
hematoxylin and eosin (H&E) staining as previously described
[9]. Briefly, all slides were stained in Richard Allan Scientific
Hematoxylin (Thermo Scientific, Waltham, MA) and Eosin-Y
(Thermo Scientific) with the Leica Autostainer (Leica
Biosystems, Buffalo Grove, IL). Immunohistochemistry was
performed with antibodies for CD4 (Leica Biosystems), CD8
(Dako, Carpinteria, CA) CD20 (Dako), and CD68 (Dako) using the
Dako Autostainer system according to manufacturer's protocol.
2.5. Image analysis and histopathology scoring
Slides were scanned using the Aperio ScanScope XT eSlide
capture device (Aperio, Vista, CA), and analyzed by Aperio
ImageScope digital analysis software (v9.1) as detailed
formerly to quantitate inflammation by H&E and to determine
lymphocyte localization by immunohistochemistry [9].
H&E-stained paraffin sections of lacrimal and salivary
glands were subjected to blinded histopathological analysis
by a board-certified veterinary pathologist (BB) as described
previously [9]. Inflammation and acinar epithelial necrosis
were scored 0–4: 0, no epithelial degeneration or necrosis and
no inflammatory cells observed in the connective tissue
between acini (inflammation within normal limits); 1, minimal
inflammation observed with few inflammatory cells present in
the connective tissue between acini and occasional cytoplas-
mic vacuolation of acinar epithelial cells; 2, mild inflamma-
tion characterized by scattered, small clusters of cells in the
connective tissue and between acini with nuclear fragmenta-
tion of some acinar epithelial cells; 3, moderate inflammation
consisting of substantial inflammatory cell presence with
larger, coalescing clusters in the connective tissue with a
widespread reduction in acinar and duct size; 4, marked
inflammation defined by inflammatory cells covering most of
the organ and an essential absence of the acinar epithelium.
Figure 1 The predominately T-cell-mediated recovery following engraftment of PBMCs from patients with Sjögren's syndrome (SjS)
is similar to healthy controls, but produces enhanced cytokine levels. PBMCs were isolated from whole blood samples obtained from
SjS patients (n = 4) or healthy controls (n = 4) and adoptively transferred intraperitoneally into NOD scid gamma (NSG) mice (at least
3 mice injected per sample) for 28 days. (A) Analysis of mouse whole blood for CD3+/CD4+ or CD3+/CD8+ T-cells by flow cytometry.
(B) Cell counts for CD3+, CD4+, and CD8+ T-cells. (C) Analysis of serum cytokines by ELISA. Values are the mean ± SD (n = 6).
* = P ≤ 0.05 versus healthy.
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Blood was collected from chimeric mice by submandibular
bleeding and leukocytes were purified for flow cytometry
using red blood cell lysis solution (eBioscience, San Diego,
CA) following the manufacturer's protocol. Cells were
labeled with antibodies for anti-human CD3 (eBioscience), CD4
(Immunotech, Vaudreuil-Dorion, Canada), CD8 (Caltag Labora-
tories, Buckingham, United Kingdom), CD20 (eBioscience),
CD14 (eBioscience), or CD56 (eBioscience) following the
manufacturer's protocol. Data was collected on the BD FACS
Calibur platform (BD Biosciences, San Jose, CA) using CellQuest
Pro (v5.1, BD Biosciences) and exported for analysis via FlowJo
(v.7.6.5, Tree Star, Inc, Ashland, OR).2.7. Cytokine ELISA
Cytokine analysis was performed on serum collected from
chimeric mice at the time of sacrifice using a cocktail of Bio-
Plex Pro® single-plex magnetic beads (Bio-Rad, Hercules, CA)
on the Bio-Plex 200 system according to the manufacturer's
protocol. Data analysis was performed using Bio-PlexManager®
(v5.0) software and results were exported to Microsoft Excel
(v2010) for further analysis.2.8. Salivary gland function
Salivary gland function was tested following pilocarpine
stimulation (1 μg/g body weight) according to previously
describedmethods [10]. Briefly,micewere restrained, injected
with pilocarpine intraperitoneally, and observed until the
appearance of saliva, which was collected for 5 min and pooled
as a measurement of salivary gland function. Weights of
collection tubes were measured individually before and after
saliva collection and the differences were recorded for analysis.
2.9. Statistics
All numerical data were expressed as mean values ± standard
deviation. Statistical differences were determined by paired,
two-tailed, Student t tests using Microsoft Excel (v2010) and
considered statistically significant if p ≤ 0.05.
3. Results
3.1. Humanized SjS mouse blood contains donor T
cells and has enhanced cytokine levels
To establish a novel chimeric mouse model of SjS, immuno-
deficient NSG mice were adoptively transferred with 5 × 106
Figure 2 Adoptive transfer of PBMCs from Sjögren's syndrome (SjS) patients into immunodeficient mice results in enhanced target
organ inflammation and reduced salivary gland function. Salivary gland and lacrimal gland tissues were harvested from chimeric mice
28 days after adoptive transfer with PBMC preparations from healthy controls or SjS patients. (A) Hematoxylin and eosin (H&E) stains
of paraffin-embedded mouse tissue sections. (B) Extent of inflammation induced by adoptive transfer of healthy or SjS cells, as
assessed quantitatively by digital image analysis of H&E slides. (C) Histopathologic scores of the H&E-stained tissue sections, as
determined by blinded semi-quantitative histopathologic analysis. (D) Salivary gland function was measured by saliva production in
mice following pilocarpine stimulation via intraperitoneal injection (1 μg/g body weight). (D) H&E stained tissue sections of NSG mice
at 28 days. Original magnification ×200. Values are the mean ± SD (n = 6). * = P ≤ 0.05 versus healthy.
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diagnosed with primary SjS [7]. At the time of transfer, all
human PBMC populations expressed similar and detectable
levels of markers for T-cells (CD3, CD4, and CD8), B-cells
(CD20), Natural killer cells (NK; CD56), and macrophages
(CD68), as determined by flow cytometry (data not shown).
Four weeks later, whole blood was collected from human-
ized mice; our results show that CD4+ and CD8+ T-cells were
the only detectable human leukocyte subsets in both
healthy and SjS chimeras (Fig. 1A). Also, no significant
differences were observed in the cell numbers for CD3+,
CD4+, and CD8+ T-cell distribution between mice receiving
SjS or healthy PBMCs (Fig. 1B). Despite positive detection
in serum from SjS patients, anti-nuclear antibodies wereFigure 3 Target organ inflammatory responses in chimeric mice
consist chiefly of CD4+ T-cells. Salivary and lacrimal gland tissue se
human CD4, CD8, CD20, CD56, and CD68 expression 28 days after a
expression within infiltrates of salivary glands (A) or lacrimal glands (B
analysis (bottom). Values are the mean ± SD and results are represe
experiments) from each PBMC source (healthy or SjS). Original magnif
all other markers within the SjS data series.not detected at 4 weeks in any chimeric mouse (unpublished
observation).
To further examine potential differences between these
humanized mice, serum from healthy and SjS chimeras was
collected at 28 days to compare human cytokine levels by
ELISA. SjS chimeras expressed increased IFN-γ by 2.4-fold
(p b 0.05), IL-10 by 2.7-fold (p b 0.05), IL-17 by 6-fold, IL-2
by 3-fold, IL-6 by 74-fold, and TNF-α by 21-fold compared to
the serum levels of cytokines in the chimeric control mice
(Fig. 1C). While levels of IL-4 (0.1 pg/mL) and IFN-α (8.4 pg/
mL) were measured in SjS chimeric mice, they were
undetectable following transfer of healthy human PBMCs
(Fig. 1C). MIP-1β expression was detected in all mice, but no
difference was observed (Fig. 1C).engrafted with PBMCs from Sjögren's syndrome (SjS) patients
ctions from NSG mice were immunohistochemically stained for
doptive transfer. (A) and (B) Inflammatory cell surface marker
), as determined by immunohistochemistry (top) and digital image
ntative of trends observed in at least 4 mice (n = 2 independent
ication ×400. * = P ≤ 0.0001 versus healthy; # = P ≤0.0001 versus
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inflammation and disease pathology
To determine the extent of inflammation in the lacrimal
and salivary glands, chimeric mouse tissue was stained with
H&E for histopathological scoring and digital image analysis.
The initial histological assessment indicated that the lacrimal
and salivary glands of SjS chimeras had markedly more
inflammation when compared to healthy PBMC adoptive
transfers (Fig. 2A). Sialoadenitis that was induced by the
transfer of human SjS PBMCs consisted primarily of lympho-
cytes, which led to destruction of acinar epithelium with
increasing inflammation. In the submandibular salivary gland,
enhanced inflammation typically was accompanied by re-
duced prominence of ducts, increased distance between ducts
due to infiltration of inflammatory cells into the connective
tissue, and acinar loss. Dacryoadenitis in the SjS chimeras also
displayed enhanced lymphocytic infiltrates and acinar epithe-
lial destruction when compared to the lacrimal glands of mice
transferred with PBMCs from healthy controls, which had little
to no inflammation present (Fig. 2A). In concordance, digital
image analysis to quantitate the extent of inflammation in the
target organs resulted in statistically significant values that
were 2-fold higher in both the salivary and lacrimal glands of
SjS chimeras (Fig. 2B). Blinded, semi-quantitative histopath-
ological scoring of H&E stains offered further confirmation of
this conclusion; healthy human PBMC transfers scored within
normal limits (0–1) for the salivary and lacrimal gland, while
those transferred from SjS patients scored 2.6 ± 0.5 (p b 0.05)
and 3.25 ± 0.5 (p b 0.05), respectively (Fig. 2C).
To demonstrate the effects and specificity of target
organ inflammation, salivary gland function was measured
and additional tissue sections were analyzed in the chimeric
mice. Saliva was collected from healthy and SjS chimeras
following pilocarpine stimulation to examine loss of end-organ
function. While no difference in salivary gland function was
observed 0, 1, or 2 weeks following adoptive transfer, saliva
production was significantly reduced 36% (p b 0.05) by SjS
cells 4 weeks post-transfer (Fig. 2D). H&E stained tissue
sections of the skin, intestine, kidney, and liver did not reveal
any substantial inflammatory responses and no histopatholog-
ical differences were observed between SjS and healthy
transfers (Fig. 2E).
3.3. Lymphocytic infiltrates of target organs are
predominately CD4+ T cells
Histopathology of salivary and lacrimal glands from SjS
patients is comprised mostly of CD4+ T-cells with CD8+ T-cells
and B-cells detected to a lesser extent, which suggests that
T-cells are the primary effector cells of target organ
inflammation and glandular dysfunction [11,12]. To charac-
terize the salivary and lacrimal gland infiltrates of our chimeric
mice, immunohistochemistry was performed to detect T-cells
(CD4 and CD8), B-cells (CD20), NK cells (CD56), and macro-
phages (CD68). Subsequently, the slides were scanned for
digital imaging and quantitative comparison by measuring the
pixel intensity of positive staining. Immunohistochemical
analysis of the salivary glands from SjS chimeras revealed an
enhancement of 2.7-fold (p b 0.0001) in CD4+ T-cells, 6.7-fold
(p b 0.0001) in CD8+ T-cells, and 4.1-fold (p b 0.0001) inB-cells when compared to PBMC transfers from healthy
controls (Fig. 3A). Further, positive staining of CD4+ T-cells in
SjS chimeras was greater by 4.4-fold (p b 0.0001) and
18.5-fold (p b 0.0001) when compared to that of CD8+ T-cells
and B-cells, respectively (Fig. 3A). Similarly, image analyses of
lacrimal gland infiltrates from SjS chimeras were significantly
greater than the control counterparts by 4.0-fold (p b 0.0001)
for CD4+ T-cells, 7.0-fold (p b 0.0001) for CD8+ T-cells, and
9.1-fold (p b 0.0001) for B-cells (Fig. 3B). Levels of CD4+
T-cells in the lacrimal glands of the SjS chimeras were also
significantly higher than CD8+ T-cells (3.3-fold; p b 0.0001)
and B-cells (15-fold; p b 0.0001) (Fig. 3B). Staining for
macrophages and NK cells revealed no significant detection
in either the lacrimal or salivary glands of all adoptively
transferred chimericmice (Fig. 3A-B). These data demonstrate
that the histological patterns of target organ inflammation in
this chimeric mouse model of SjS are largely within the
pathological spectrum of what is observed in SjS patients with
notable exceptions [13].4. Discussion
In order for novel therapies targeting specific immune cell
function to move forward in human clinical trials, it is
critical to examine the potential efficacy/side effects in
established preclinical animal models. However, an animal
model of SjS that is suitable for early drug discovery is not
yet available. In this work, we have developed a novel SjS
chimeric model to replicate T-cell mediated autoimmune
pathology in vivo. This humanized mouse model could be an
appropriate platform to be used in the discovery of
therapeutic alternatives to the current management of SjS,
which is non-specific and largely supportive.
Since graft versus host inflammation is not observed in
the NSG mouse strain for at least 30 days following adoptive
transfer [5], we exploited this 4-week timeframe to explore
human SjS autoimmune responses in our mouse chimeras.
The transfer of PBMCs from SjS patients results in robust
CD4+ T-cell infiltration in the salivary and lacrimal glands at
28 days when compared to transfers from healthy subjects.
Notably, chimeric mice receiving healthy PBMCs did have
detectable levels of infiltrate in the salivary and lacrimal
glands at 28 days. This may be attributable to the propensity
of NOD mice to develop sialoadenitis and that this
autoimmune phenotype is transferrable to NOD-scid mice
[6], which indicates that an environment permissive to an
inflammatory response is presumably present to some extent
already in the NSG mice.
While the circulating T-cell distribution was similar in all
chimeric mice in this study, mice transferred with PBMCs
from SjS patients produced significantly higher levels of
IFN-γ, IL-6, IL-10, IL-17, and TNF-α. Accordingly, both IFN-γ
and IL-10 were found to be elevated in peripheral blood
T-cells of SjS patients [14]. IFN-γ and TNF-α are major
cytokines involved in the promotion of Th1 pro-inflammatory
responses and have been shown to be elevated in the saliva
of SjS patients [15]. Moreover, mouse models of SjS have
shown that IFN-γ deficiency prevents clinical onset and tissue-
specific autoimmune responses [16]. Despite the traditional
role as a Th2 anti-inflammatory cytokine, IL-10 levels are
elevated in the serum [17] of SjS patients and correlate with
7Chimeric human–mouse model of Sjögren's syndromedisease activity, thus suggesting a potentially pathogenic role
for IL-10 in the presence of IFN-γ [18]. In addition, IL-6 and
IL-17 are cytokines involved in the Th17 pathway and have been
implicated in multiple autoimmune diseases, including SjS.
Considering the recent success using monoclonal antibodies to
neutralize inflammatory mediators in the treatment of other
autoimmune disorders, our results suggest targeting of IFN-γ,
IL-17, and IL-10 as a viable therapeutic strategy to treat SjS.
Furthermore, since some degree of activation of Th1, Th2, and
Th17 pathways is observed both in this model and in human SjS,
these chimeras may provide an ideal study medium to examine
the differential blockade of each of these pathways on the final
disease state to determine the pathological role of each.
Our histopathological and immunohistochemical findings
recapitulate what is seen with regard to T-cells in SjS patients,
which renders this model useful for the study of molecular-
based therapies to treat and prevent disease pathology.
Additionally, because immunohistochemical data on lacrimal
glands in SjS is lacking due to the inaccessibility of this tissue in
humans for biopsy, our model provides a mechanism to analyze
this tissue. Our data indicate that the extent and pattern of
inflammation in the lacrimal gland are indeed similar to the
salivary gland in SjS. Histopathological scores of SjS chimeras
were defined by enhanced lymphocytic infiltrates and acinar
epithelial necrosis, leading to a widespread reduction in duct
size. Digital imaging of immunohistochemistry showed that
salivary and lacrimal gland infiltrates were predominately CD4+
T-cells, with minimal levels of CD8+ T-cells and B-cells. In
concordance, previous work has demonstrated that CD4+ T-cells
predominate the salivary gland infiltrate of SjS patients [1] and
that these cells are largely responsible for mediating glandular
destruction [3]. Consistent with previously published studies
demonstrating possible roles for other immune cells in
SjS, B-cells were present at significantly greater levels in
lacrimal and salivary gland infiltrates when compared to
transfers from healthy donors [2].5. Conclusion
Collectively, adoptive transfer of PBMCs from SjS patients
into NSG mice should be a novel chimeric mouse model of SjS
that will allow the in vivo study of autoimmune-mediated
inflammation on human immune cells and opens new avenues
to study disease progression and therapeutic intervention.
Although, considering the heterogeneity of SjS and that the
disease transferred in this model will be patient-specific,
therapeutic efficacy would have to be demonstrated in
adoptive transfers from a number of patients before reaching
definitive conclusions. Further examination using this SjS
model will be in characterizing the in situ glandular histopa-
thology of SjS chimeras. Subsequently, this model will be used
to examine gene expression and characterize the effector
T-cell population to facilitate the investigation of molecular-
based therapies to prevent target organ inflammation in SjS
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